v3.26.1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Millions	Mar. 31, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 2,962.6	$ 3,118.1
Marketable securities	5,791.1	5,487.1
Accounts receivable, net	5,731.0	5,741.1
Inventories	3,103.6	3,200.8
Prepaid expenses and other current assets	620.9	474.8
Total current assets	18,209.2	18,021.9
Marketable securities	9,786.0	10,260.6
Property, plant, and equipment, net	5,266.1	5,120.4
Intangible assets, net	1,286.9	1,257.4
Deferred tax assets	4,190.9	4,077.2
Other noncurrent assets	2,129.7	1,821.2
Total assets	40,868.8	40,558.7
Current liabilities:
Accounts payable	1,027.1	939.0
Accrued expenses and other current liabilities	2,724.4	2,876.4
Finance lease liabilities	720.0	0.0
Deferred revenue	636.2	553.0
Total current liabilities	5,107.7	4,368.4
Long-term debt	1,986.2	1,985.9
Finance lease liabilities	0.0	720.0
Deferred revenue	225.1	208.7
Other noncurrent liabilities	2,126.2	2,018.8
Total liabilities	9,445.2	9,301.8
Stockholders' equity:
Preferred Stock, par value $.01 per share; 30.0 shares authorized; shares issued and outstanding - none	0.0	0.0
Additional paid-in capital	14,401.3	13,995.0
Retained earnings	36,423.8	35,797.1
Accumulated other comprehensive income	11.9	77.5
Treasury Stock, at cost; 34.7 shares in 2026 and 33.7 shares in 2025	(19,413.5)	(18,612.8)
Total stockholders' equity	31,423.6	31,256.9
Total liabilities and stockholders' equity	40,868.8	40,558.7
Class A Stock
Stockholders' equity:
Common stock	0.0	0.0
Common Stock
Stockholders' equity:
Common stock	$ 0.1	$ 0.1

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

REGENERON PHARMACEUTICALS, INC. 10-Q